EKElena V. Karabina

Elena V. Karabina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena V. Karabina has a total of 293 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)

    by Ya. V. Gridneva, M. I. Volkova, Yu. V. Anzhiganova, V. S. Bragina, В. А. Водолазский, M. I. Gluzman, R. A. Zukov, A. M. Ivanov, E. R. Israelyan, E. V. Karabina, et al.

    Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.


  • Open Access

    Erratum in "The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: a retrospective study" (DOI: 10.26442/18151434.2024.4.203108)

    by Elena V. Karabina, Dina D. Sakaeva, Оleg N. Lipatov

    In the article «The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: A retrospective study», published in the Journal of Modern Oncology, Vol. 26, No.4, 2024 (DOI: 10.26442/18151434.2024.4.203108), errors were made: The number of used medicinal products (MPs) was corrected in the sentence "The use of 47 MPs was reported, including 46 antitumor agents and drugs with antitumor activity as part of 73 antitumor drug therapy regimens". Correct wording of the sentence: "The use of 46 MPs as part of 73 antitumor drug therapy regimens was reported". The names of 3 drugs and 1 applied regimen in 4 rows of the table have been corrected. Table row: The correct version: 36 Palbociclib + fulvestrant Palbociclib 36 Palbociclib + fulvestrant Cyclophosphamide Table row: The correct version: 46 Docetaxel + carboplatin + trastuzumab Cyclophosphamide 46 Docetaxel + carboplatin + trastuzumab Calcium folinate Table row: The correct version: 47 Capecitabine + bevacizumab Calcium folinate 47 Capecitabine + bevacizumab – Table row: The correct version: 70 FOLFIRINOX + bevacizumab (oxaliplatin, irinotecan,calcium folinate, fluorouracil, bevacizumab) – 70 FOLFOXIRI + bevacizumab (oxaliplatin, irinotecan,calcium folinate, fluorouracil, bevacizumab) – The errors were corrected at the request of the authors' team. The publisher replaced the original version of the published article with the corrected one; the information on the website was also corrected. The publisher apologizes to readers and authors for the errors and is confident that the correction of errors will ensure the correct perception and interpretation of the results of the study described in the text.

  • Open Access

    Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in BRAF metastatic melanoma: updated 4-year OS analyses

    by I. V. Samoylenko, Yu. M. Kolontareva, E. V. Kogay, N. V. Zhukova, I. A. Utyashev, M. E. Ivannikov, K. V. Menshikov, M. V. Zinkevich, K. V. Orlova, Yu. V. Vakhabova, et al.

    Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.

  • Open Access

    Real-world efficacy and safety of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: Updated data from a Russian observational study

    by Maria I. Volkova, Alexey S. Kalpinskiy, Olesya A. Goncharova, Konstantin V. Menshikov, Olesia A. Stativko, Elena V. Karabina, Aleksandr S. Dergunov, Natalya I. Polshina, Elena N. Alexandrova, Andrey A. Lebedinets, et al.

    Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.


  • Open Access

    Safety of the Off-Label Use of Antitumor Drugs in Real Clinical Practice: Experience of Oncologists of the Russian Federation

    by E. V. Каrabina, D. D. Sakaeva, O. N. Lipatov

    Introduction. One of the key issues associated with the off-label use of antitumor drugs is safety. Typically, the advantages of such prescriptions in oncology are linked to the potential clinical benefits outweighing the risks of complications.Aim. To assess the safety of the off-label antitumor drug therapy in comparison with the on-label drug administration in the context of real clinical practice among oncologists in the Tula region.Materials and methods. The study was conducted at the Tula Regional Clinical Oncology Center, Russia. Over a six-month period in 2019, clinical data, provided by the regional information system, were analyzed for 919 completed treatment cases of 201 patients over 18 years of age who received antitumor drug therapy for malignant neoplasms. The study enrolled patients who had at least one hospitalization and got off-label antitumor drug therapy, as well as those receiving on-label drug treatment. The study assessed the safety of the off-label antitumor drug therapy in comparison with that of the on-label treatment, estimating the frequency of adverse events (AEs), spectrum of adverse events, severity of adverse events, fatal outcomes, treatment delays and discontinuations, and hospitalizations due to toxicity. A comparative analysis involved the results of using off-label and on-label antitumor drug therapy in terms of the aforementioned parameters. Results and discussion. No unforeseen adverse events were revealed in the study. The spectrum of adverse events encompassed 40 clinical and laboratory abnormalities with varying frequencies across the studied groups. Adverse events were observed in the majority of patients across both studied groups (83% and 86%). A predominance of grade I and II toxicity was noted. In some instances, therapy was discontinued and treatment was suspended; however, the frequency of these occurrences was significantly lower compared to current literature data. One fatal outcome due to complications from the administered therapy was recorded. All adverse events were reported in both studied groups with similar frequencies. The most commonly observed adverse events in both groups included hepatotoxicity, anemia, thrombocytopenia, nephropathy, cephalalgia, leukocytosis, skin toxicity, dyslipidemia, hypertension, bone pain syndrome, and dizziness. Other adverse events occurred sporadically with similar frequency. The most severe presentations were noted in the following adverse events: thrombocytopenia, gastrointestinal toxicity, leukocytosis, hyperglycemia, and immune-mediated diabetes mellitus with ketoacidotic coma.Conclusion. In real clinical practice, the safety of off-label and on-label antitumor drug therapy reveals no significant difference.

  • Open Access

    Safety of the Off-Label Use of Antitumor Drugs in Real Clinical Practice: Experience of Oncologists of the Russian Federation

    by E. V. Каrabina, D. D. Sakaeva, O. N. Lipatov

    Introduction. One of the key issues associated with the off-label use of antitumor drugs is safety. Typically, the advantages of such prescriptions in oncology are linked to the potential clinical benefits outweighing the risks of complications.Aim. To assess the safety of the off-label antitumor drug therapy in comparison with the on-label drug administration in the context of real clinical practice among oncologists in the Tula region.Materials and methods. The study was conducted at the Tula Regional Clinical Oncology Center, Russia. Over a six-month period in 2019, clinical data, provided by the regional information system, were analyzed for 919 completed treatment cases of 201 patients over 18 years of age who received antitumor drug therapy for malignant neoplasms. The study enrolled patients who had at least one hospitalization and got off-label antitumor drug therapy, as well as those receiving on-label drug treatment. The study assessed the safety of the off-label antitumor drug therapy in comparison with that of the on-label treatment, estimating the frequency of adverse events (AEs), spectrum of adverse events, severity of adverse events, fatal outcomes, treatment delays and discontinuations, and hospitalizations due to toxicity. A comparative analysis involved the results of using off-label and on-label antitumor drug therapy in terms of the aforementioned parameters. Results and discussion. No unforeseen adverse events were revealed in the study. The spectrum of adverse events encompassed 40 clinical and laboratory abnormalities with varying frequencies across the studied groups. Adverse events were observed in the majority of patients across both studied groups (83% and 86%). A predominance of grade I and II toxicity was noted. In some instances, therapy was discontinued and treatment was suspended; however, the frequency of these occurrences was significantly lower compared to current literature data. One fatal outcome due to complications from the administered therapy was recorded. All adverse events were reported in both studied groups with similar frequencies. The most commonly observed adverse events in both groups included hepatotoxicity, anemia, thrombocytopenia, nephropathy, cephalalgia, leukocytosis, skin toxicity, dyslipidemia, hypertension, bone pain syndrome, and dizziness. Other adverse events occurred sporadically with similar frequency. The most severe presentations were noted in the following adverse events: thrombocytopenia, gastrointestinal toxicity, leukocytosis, hyperglycemia, and immune-mediated diabetes mellitus with ketoacidotic coma.Conclusion. In real clinical practice, the safety of off-label and on-label antitumor drug therapy reveals no significant difference.

  • Open Access

    The reasons for prescribing antitumor drugs beyond the registered indications in real clinical practice: A retrospective study

    by Elena V. Karabina, Dina D. Sakaeva, Оleg N. Lipatov

    Aim. To study the reasons for prescribing antitumor drugs (ATDs) beyond the registered indications (BRIs) in real clinical practice. Materials and methods. The study was conducted at the Tula Regional Clinical Oncology Center. For 6 months of 2019, information was analyzed on 919 completed cases of treatment of 201 patients over the age of 18 who received antitumor drug therapy for morphologically verified solid malignant neoplasms in the inpatient department of the medical organization using a regional information system. Completed cases of treatment with ATDs were copied BRIs and in accordance with the registered indications. The analysis of the literature devoted to the study of the causes of the use of ATDs outside the registered indications has been carried out. The reasons for prescribing ATDs BRIs in real clinical practice were studied when analyzing completed cases of treatment of patients receiving appropriate therapy. Results. In 86.2% of cases, the main reason for the use of antitumor drug therapy BRIs is associated with the presence of antitumor agents in clinical guidelines and recommendations of professional communities. 11.6% of cases of prescribing antitumor agents BRIs were associated with burdened clinical situations: exhaustion of the possibilities of registered therapy; lack of treatment options for rare forms of neoplasms; lack of alternative options with contraindications to standard treatment methods. Other reasons for prescribing the above mentioned treatment were extremely rare and were situational in nature. Conclusion. In the vast majority of cases, the main reason for prescribing ATDs BRIs is the presence of these agents in clinical guidelines and recommendations of professional communities. The second most common cause is associated with burdened clinical situations. The information obtained indicates that the use of ATDs in cancer patients is an integral part of routine clinical practice and in the future can be used to improve the regulatory regulation of these prescriptions.

  • Open Access

    Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma

    by M. I. Volkova, A. S. Kalpinskiy, О. A. Goncharova, К. V. Menshikov, O. A. Stativko, E. V. Karabina, A. S. Dergunov, N. I. Polshina, E. N. Aleksandrova, A. A. Lebedinets, et al.

    Objective: to re-evaluate the efficacy and safety of lenvatinib with pembrolizumab in unselected Russian renal cell carcinoma (RCC) patients, included in the phase IV study, in a median follow-up extended to 17.1 months. The primary end point was progression-free survival (PFS), secondary end points were overall survival (OS), objective response rate (ORR) and duration of response (DOR), disease control rate (DCR) and its duration, as well as safety.Materials and methods. The study included medical data of 165 patients with verified advanced RCC who received lenvatinib with pembrolizumab in 36 centers of the Russian Federation from 05.02.2018 to 25.07.2024. The median age was 60 (20–76) years, the male to female ratio was 2.3:1. The majority of patients had Karnofsky performance status ³80 % (74.6 %), clear cell RCC (93.3 %) without sarcomatoid differentiation (93.3 %), metachronous metastases (50.9 %) localized in 1 organ (75.2 %), were nephrectomized (63.0 %) and did not receive antitumor therapy (91.0 %). At the time of lenvatinib with pembrolizumab therapy start 40 patients (24.2 %) were classified into International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable prognostic group, 92 (55.8 %) in the intermediate prognostic group, and 33 (20.0 %) in the poor prognostic group. The median follow-up was 17.1 (1.5–72.9) months.Results. The median PFS achieved 24.0 (18.7–29.3) months, 17-month PFS 60.5 %. The median OS was 48.9 (18.5– 79.2) months, 17-month OS – 76.1 %. Objective response was registered in 46.0 % of patients including 2.4 % complete responders; the DCR was 92.1 %. The median DOR was 16.6 (2.1–72.9) months, duration of disease control –14.3 (2.1–72.9) months. Confirmed dynamics of change in the sum of tumor foci diameters was recorded in 152 patients, while the median change was –25 % (from –100 % to +29 %). Any decrease in the sum of tumor foci diameters occurred in 69.1 % of cases. The incidence of any adverse events (AE) was 78.2 %, severe AE – 24.2 %, and serious AE – 9.7 %. Immune-mediated AEs developed in 17.0 % of cases and AE grades 3–4 in 6.7 % of cases. Mortality from AEs was 1.2 %.Conclusion. Compared with the registration study, in real-world clinical practice in patients with advanced RCC the lenvatinib with pembrolizumab provides a lower ORR with comparable PFS and OS rates and demonstrates a satisfactory safety profile.


  • Open Access

    The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia

    by A. E. Protasova, A. A. Rumyantsev, M. Yu. Sheremet, A. Yu. Goryainova, М. В. Волконский, A. G. Kedrova, S. V. Kuzmicheva, O. N. Aymamedova, Kh. S. Musaeva, S. M. Soroka, et al.

    Background. Endometrial cancer (EC) treatment outcomes need to be improved. Immunotargeted therapy lead to long-term and delayed effects compared to chemotherapy. Estimation of long-term efficacy and quality of life are crucial when we are talking about efficacy in whole.Aim. To evaluate the long-term clinical efficacy of lenvatinib plus pembrolizumab therapy in patients with EC.Materials and methods. The study included 43 patients with stages I-IV EC with mismatch repair-proficient tumors and treatment duration of more than 9 months. We evaluated median progression-free survival, objective response, duration of treatment depending on the line of therapy, prevalence and type of adverse events, and correction regimens. Results. Lenvatinib plus pembrolizumab treatment was safe and efficacious in recurrent EC. Median of progression-free survival (patients with response or stabilization more than 9 months) is 10.2 months (95 % confidence interval 9.1-13.0), median of follow up is 9.7 (1.4-33.8) months. There were no complete responses, partial response was in 12 (28 %) patients, disease stabilization was in 31 (72 %) patients. Regarding safety, the overall rate of any-grade adverse events was 56.3 %. The most common treatment-related adverse events were fatigue (32.6 %), hypertension (23.3 %), and hypothyroidism (18.6 %). Dose reduction was performed in 22 (51.2 %) patients.Conclusion. The combination of lenvatinib plus pembrolizumab has long-term efficacy and manageable profile of safety. The presence of a significant pool of patients with durable response allows improving the survival rate of such patients in Russia.

  • Cost of supportive cancer care in the Russian Federation. Part 2

    by I.A. Zheleznyakova, E.I. Rumyantseva, O.S. Plakhotnik, I.A. Alexandrov, T.S. Vakhrusheva, G.V. Trifonova, E.A. Sidorova, A.S. Yakina, E.S. Samsonova, I.A. Mikhailov, et al.

    Objective. To assess the cost of supportive drug therapy for 10 complications of malignant neoplasms according to the recommendations of the Russian Public Organization «Russian Society of Clinical Oncology» (RUSSCO). Material and methods. Considering the RUSSCO recommendations, we estimated drug therapy regimens for the following complications: anemia, hepatotoxicity, dermatological reactions, cardiovascular toxicity, neurological complications, nephrotoxicity, effects of extravasation, febrile neutropenia, nausea and vomiting, central venous access. To estimate the population requiring supportive therapy, we used data from registers of medical care bills for 2022. These reports contain information on the number of completed cases of antitumor drug therapy and the number of patients who received treatment. Literature data on the incidence of the above-mentioned complications were also used. Results. The largest financial costs (63.8% of all complications) were observed for the treatment of anemia (4 721 896 721.06 rubbles), hepatotoxicity (3 545 843 422.82 rubbles) and consequences of extravasation (2 388 137 692.57 rubbles). The oncology profile accounts for 66% of the estimated funding within this model. In the current model, 34% of the need is for preferential drug provision, 37% is additional need for compulsory medical insurance to finance the added cost of hospital-stay in a day hospital and 31% in a 24-hour hospital. Conclusion. These findings complement the previously published results for other complications presented in the RUSSCO recommendations. Calculation methodology and appropriate data can underlie further improvement of financing of supportive cancer therapy.